Cowen reaffirmed their buy rating on shares of Ovid Therapeutics (NASDAQ:OVID) in a research report sent to investors on Sunday, AnalystRatings.com reports.

Several other research analysts also recently weighed in on OVID. Zacks Investment Research downgraded Ovid Therapeutics from a buy rating to a hold rating in a research note on Friday, February 22nd. JMP Securities dropped their price target on Ovid Therapeutics from $26.00 to $11.00 and set an outperform rating on the stock in a research note on Friday, March 8th. Piper Jaffray Companies dropped their price target on Ovid Therapeutics to $14.00 and set an overweight rating on the stock in a research note on Sunday, March 10th. Finally, LADENBURG THALM/SH SH set a $27.00 price target on Ovid Therapeutics and gave the company a buy rating in a research note on Friday, March 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $12.85.

Shares of OVID stock opened at $1.74 on Friday. Ovid Therapeutics has a 1-year low of $1.56 and a 1-year high of $11.45. The company has a current ratio of 7.78, a quick ratio of 7.78 and a debt-to-equity ratio of 0.02. The firm has a market cap of $64.23 million, a P/E ratio of -0.82 and a beta of 2.10.

Ovid Therapeutics (NASDAQ:OVID) last announced its earnings results on Tuesday, May 7th. The company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.04). On average, equities research analysts forecast that Ovid Therapeutics will post -1.87 earnings per share for the current fiscal year.

In other news, CEO Jeremy M. Levin purchased 75,000 shares of the company’s stock in a transaction on Friday, February 22nd. The shares were acquired at an average price of $2.00 per share, for a total transaction of $150,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 43.90% of the stock is currently owned by insiders.

Several hedge funds have recently modified their holdings of the company. Rhumbline Advisers lifted its holdings in shares of Ovid Therapeutics by 47.2% in the 4th quarter. Rhumbline Advisers now owns 16,551 shares of the company’s stock valued at $40,000 after buying an additional 5,310 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Ovid Therapeutics by 7.1% in the 4th quarter. Geode Capital Management LLC now owns 95,865 shares of the company’s stock valued at $231,000 after buying an additional 6,391 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Ovid Therapeutics by 11.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 87,257 shares of the company’s stock valued at $211,000 after buying an additional 8,995 shares during the period. SG Americas Securities LLC acquired a new position in shares of Ovid Therapeutics in the 4th quarter valued at about $46,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Ovid Therapeutics by 136.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 54,832 shares of the company’s stock valued at $311,000 after buying an additional 31,687 shares during the period. 17.55% of the stock is owned by institutional investors and hedge funds.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.

Further Reading: Why do commodities matter?

Analyst Recommendations for Ovid Therapeutics (NASDAQ:OVID)

Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.